Skip to main content

Table 2 Comparison of CD30 reactivity between flow cytometry by PRIME-F notation and immunohistochemistry by PRIME-I notation

From: Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells

 

Subclassificatioin

Site

PRIME-F notation for FCM

Notation level

PRIME-I notation for IHC

1

AITL

LN

->> > (dim)+

I

–

2

AITL

tonsil

->> > (dim)+

I

–

3

ATL

LN

->> > (dim)+

I

–

4

ATL

LN

->> > (dim)+

I

–

5

ATL

LN

->> > (dim)+

I

–

6

ENKL

nasal cavity

->> > (dim)+

I

->> > (weak) + a

7

PTCL

stomach

->> > (dim)+

I

->> > +/(weak) + a

8

ENKL

nasal cavity

->> > (dim)+

I

-> > +/(weak)+

9

PTCL

skin

->> > (dim)+

I

-> > +/(weak)+

10

PTCL/FHT

LN

->> > (dim)+

I

-> > +

11

ENKL

nasal cavity

->> > (dim)+

I

- > (very weak)+> > (weak)+

12

ATL

LN

->> > (dim)+

I

+/(weak)+/−

13

ALCL

LN

->> > +

I

+

14

FTL

LN

-> > (dim)+

II

–

15

FTL

LN

-> > (dim)+

II

–

16

PTCL/FHT

LN

-> > (dim)+

II

–

17

ATL

LN

-> > (dim)+

II

->> > (very weak) + a

18

ATL

LN

-> > (dim)+

II

->> > (weak) + a

19

ENKL

nasal cavity

-> > (dim)+

II

-> > (weak)+

20

PTCL

LN

-> > (dim)+

II

-> > (weak)+ > +

21

PTCL

LN

-> > (dim)+

II

-> > +/(weak)+

22

ATL

LN

-> > (dim)+

II

- > (very weak)+

23

ENKL

LN

-> > (dim)+

II

(very weak)+/−

24

ATL

LN

-> > (dim)+

II

+/(weak)+/−

25

PTCL

LN

-> > (dim)+

II

(weak)+>/(very weak)+ > −

26

ATL

LN

-> > (dim)+ > +

II

->> > (weak) + a

27

PTCL

LN

-> > (dim)+ > +

II

-> > + > (weak)+

28

PTCL

LN

-> > (dim)+ > +

II

-> > +/(weak)+

29

FTL

thyroid gland

- > (dim)+ > +

III

- > (weak)+

30

ENKL

nasal cavity

- > (dim)+

III

-> > (weak)+

31

ATL

LN

- > (dim)+

III

+/(weak)+/−

32

AITL

LN

(dim)+

IV

+/(weak)+/−

33

ATL

LN

(dim)+

IV

+/(weak)+/−

34

ATL

LN

(dim)+

IV

+/(weak)+> > −

35

ATL

skin

(dim)+

IV

+/(weak)+

36

PTCL

LN

(dim)+

IV

+

37

ALCL

testis

(dim)+

IV

+

38

PTCL

tonsil

(dim)+> > +

IV

- > (weak)+ > +

39

ALCL

LN

+/(dim)+/−

V

+> > (weak)+

40

ALCL

LN

+ > (dim)+ > −

V

+

41

PTCL

LN

+ > (dim)+

V

+/(weak)+> > −

42

ATL

LN

+>> > (dim)+

V

+/(weak)+/(very weak)+

43

PTCL

LN

+>> > (dim)+

V

+

44

ATL

LN

+> > (dim)+

V

+/(weak)+/−

45

ATL

skin

+> > (dim)+

V

+ > (weak)+> > (very weak)+

46

ATL

LN

+> > (dim)+

V

+

47

ALCL

LN

+

V

+>> > (weak)+

48

PTCL

LN

+

V

+> > (weak)+

49

ATL

LN

+

V

+

50

PTCL/γδ-T

pleural effusion

(bright)+>> > +/(dim)+

V

+

51

ALCL

bone

(bright)+

V

+ > (weak)+ > −

52

PTCL/γδ-T

skin

(bright)+

V

+

  1. Abbreviations: FCM flow cytometry, LN lymph node, FTL follicular T-cell lymphoma, FHT follicular/helper phenotype, PTCL peripheral T-cell lymphoma/NOS, AITL angioimmunoblastic T-cell lymphoma, ENKL extranodal NK/T-cell lymphoma/nasal type, ATL adult T-cell lymphoma, ALCL anaplastic large cell lymphoma
  2. apercentage of CD30-positive cells is less than 10%
  3. PRIME-F notation level is classified as follows. I, II, III: notations starting with ‘-’ followed by 3, 2, 1 “>”, respectively. IV: notation starting with ‘(dim)+’. V: notations starting with ‘+’ or ‘(bright)+’
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us